Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can an app save kidneys and the planet? new study investigates

NCT ID NCT07613593

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 07, 2026 · Updated 2 times

Summary

This study will look at how people with chronic kidney disease use a digital app called MyRenalCare. Researchers want to see if the app helps improve health, lowers hospital visits, and reduces costs and environmental impact. About 1,000 adults under kidney care will be included.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2026

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

* Retrospective: \~450-500 existing users + matched controls(24 months data). * Comparison with entire WKC CKD population * Prospective: \~500-550 new users + matched controls (6 months). * Exploratory: \~500 dialysis or pre transplant MyRenalCare users (no matched controls). * Qualitative: 15-25 patients + 10-15 staff.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 5.1.1 Inclusion criteria - MyRenalCare users (retrospective and prospective cohorts) Adults will be eligible for inclusion in the MyRenalCare cohorts if they meet all of the following: 1. Aged 18 years or over. 2. Under the care of the Wessex Kidney Centre 3. Registered with, or offered and subsequently enrolled onto, the MyRenalCare platform during the defined retrospective or prospective periods. 4. Able to understand study information and, where applicable, provide informed consent for use of their data for research purposes. Specific CKD stage definitions and thresholds (e.g. based on eGFR, albuminuria or uPCR) will be documented in the study manual to ensure consistent application. 5.1.2 Inclusion criteria - matched usual care controls Adults will be eligible for inclusion in the matched control cohorts if they meet all of the following: 1. Aged 18 years or over. 2. Under the care of the Wessex Kidney Centre for chronic kidney disease. 3. Not registered with or using MyRenalCare at any point during the relevant observation period. 4. Have sufficient clinical and administrative data available in the renal electronic patient record to enable matching and outcome assessment. Controls will be identified retrospectively from the renal electronic patient record and matched to MyRenalCare users using a predefined matching strategy. 5.1.3 Inclusion criteria - qualitative interview participants (patients and staff) Patients will be eligible to take part in the qualitative interview component if they meet all of the following: 1. Aged 18 years or over. 2. Currently using, or recently offered, the MyRenalCare platform as part of their CKD care at the Wessex Kidney Centre. 3. Able to understand spoken and written English to the extent required for participation in an interview. 4. Able and willing to provide written informed consent for participation in a recorded interview. 5. Belong to a demographic or clinical subgroup of interest for the study (e.g. varying age, ethnicity, CKD stage, or digital engagement level), as part of purposive sampling to support diversity and equity analysis. Clinical staff will be eligible if they meet all of the following: 1. Employed by PHU or working in direct partnership with the Wessex Kidney Centre. 2. Directly involved in the care of patients with chronic kidney disease and/or in the implementation or support of MyRenalCare. 3. Able and willing to provide informed consent for a recorded interview. 4. Able to reflect on experiences and observations relevant to the delivery, uptake, or equity implications of digital health in CKD. Exclusion Criteria: 1. Patients with acute kidney injury without established chronic kidney disease. 2. Patients with a very limited life expectancy where participation in routine digital monitoring is not appropriate, as judged by the clinical team. 3. Patients who have previously indicated that they do not wish their routinely collected clinical data to be used for research where such opt-out applies to this study. 4. Patients who are unable to be identified reliably in the available data sources (for example, inconsistent or missing key identifiers). 5. Any other situation where, in the opinion of the responsible clinician, participation in the study processes (including data use) would be inappropriate or unduly burdensome. 6. Clinical staff who are not directly involved in the care of patients with chronic kidney disease or in the implementation of the MyRenalCare platform. 7. Staff members currently on extended leave or unable to participate during the data collection period. 8. Individuals who do not wish to have their views included in recorded interview transcripts or are unable to provide informed consent for participation. 9. Any situation where, in the opinion of the study team or the individual's manager, participation would be inappropriate or burdensome due to role, availability, or conflict of interest.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic kidney disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Portsmouth Hospitals University NHS Trust

    RECRUITING

    Portsmouth, Hampshire, PO6 3LY, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.